The burden of COVID-19 has been noted to be disproportionately greater in minority women, a population that is nevertheless still understudied in COVID-19 research . We conducted an observational study to examine COVID-19-associated mortality and cardiovascular disease outcomes after testing (henceforth index) among a racially diverse adult women veteran population . We assembled a retrospective cohort from a Veterans Affairs (VA) national COVID-19 shared data repository, collected between February and August 2020 . A case was defined as a woman veteran who tested positive for SARS-COV-2, and a control as a woman veteran who tested negative . We used Kaplan-Meier curves and the Cox proportional hazards model to examine the distribution of time to death and the effects of baseline predictors on mortality risk . We used generalized linear models to examine 60-day cardiovascular disease outcomes . Covariates studied included age, body mass index (BMI), and active smoking status at index, and pre-existing conditions of diabetes, chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), and a history of treatment with antiplatelet or anti-thrombotic drug at any time in the 2 years prior to the index date . Women veterans who tested positive for SARS-CoV-2 had 4 times higher mortality risk than women veterans who tested negative (Hazard Ratio 3.8 , 95% Confidence Interval CI 2.92 to 4.89) but had lower risk of cardiovascular events (Odds Ratio OR 0.78 , 95% CI 0.66 to 0.92) and developing new heart disease conditions within 60 days (OR 0.67 , 95% CI 0.58 to 0.77). Older age, obesity (BMI> 30), and prior CVD and COPD conditions were positively associated with increased mortality in 60 days . Despite a higher infection rate among minority women veterans, there was no significant race difference in mortality, cardiovascular events, or onset of heart disease . SARS-CoV-2 infection increased short-term mortality risk among women veterans similarly across race groups . However, there was no evidence of increased cardiovascular disease incidence in 60 days . A longer follow-up of women veterans who tested positive is warranted.